Reivindicaciones

CLAIMS 1. Inhibitors of the S100 calcium-binding protein A9 (S100A9) /S100A8 - Toll Like Receptor 4 (TLR4) dimer-receptor axis for use in the treatment of heart failure with preserved ejection fraction (HFpEF) , through attenuating the deleterious effect of EVs on endothelial function and prevention of a pro-fibrotic phenotype. 2. Use according to claim 1 wherein the said inhibitors comprise Resatorvid (TAK-242, CLI095) ; Eritoran; Dutasteride (DB01126) ; Buclizine (DB00354) ; Conivaptan (DB00872) ; Lomitapide (DB08827) ; Adapalene (DB00210) ; Lumacaftor (DB09280) ; Dihydroergotamine (DB00320) ; Bromocriptine (DB01200) ; Tolvaptan (DB06212) Nandrolone phenpropionate (DB00984) ; Flunarizine (DB04841) ; Irinotecan (DB00762) ; Dihydrotachysterol (DB01070) ; Antrafenine (DB01419) ; Nilotinib (DB04868) ; Medrogestone (DB09124) ; Itraconazole (DB01167) ; Doxercalci f erol (DB06410) ; Ponatinib (DB08901) ; Netupitant (DB09048) ; Difenoxin (DB01501) ; Paricalcitol (DB00910) ; Pimozide (DB01100) ; Tasosartan (DB01349) ; Alfacalcidol (DB01436) ; Fluspirilene (DB04842) ; Azilsartan medoxomil (DB08822) ; Cabozantinib (DB08875) ; Lorpiprazole (DB09195) Ergocalciferol (DB00153) ; Loperamide (DB00836) ; Drospirenone (DB01395) Pranlukast (DB01411) ; Ziprasidone (DB00246) ; Meclizine (DB00737) ; Sertindole (DB06144) ; Lurasidone (DB08815) ; Vorapaxar (DB09030) ; Umeclidinium (DB09076) , as well as S100A9 Inhibitors, such as ABR-238901; Tasquinimod (ABR-215050 ) ; Paquinimod (ABR 25757) ; laquinimod (ABR-215062 ) ; Roquinimex (ABR212626) ; Azeliragon; FPS-ZM1; RAGE 229; AC-73; antagonist peptide-9 (AP9) and combinations thereof . 3. Pharmaceutical formulation for use for use in the treatment of HFpEF characterized by comprising inhibitors of the S100A9/S100A8-TLR4 dimer-receptor axis. 4. Pharmaceutical formulation according to claim 3 wherein the said inhibitors comprise Resatorvid (TAK-242, CLI095) ; Eritoran; Dutasteride (DB01126) ; Buclizine (DB00354) ; Conivaptan (DB00872) ; Lomitapide (DB08827) ; Adapalene (DB00210) ; Lumacaftor (DB09280) ; Dihydroergotamine (DB00320) ; Bromocriptine (DB01200) ; Tolvaptan (DB06212) Nandrolone phenpropionate (DB00984) ; Flunarizine (DB04841) ; Irinotecan (DB00762) ; Dihydrotachysterol (DB01070) ; Antrafenine (DB01419) ; Nilotinib (DB04868) ; Medrogestone (DB09124) ; Itraconazole (DB01167) ; Doxercalcif erol (DB06410) ; Ponatinib (DB08901) ; Netupitant (DB09048) ; Difenoxin (DB01501) ; Paricalcitol (DB00910) ; Pimozide (DB01100) ; Tasosartan (DB01349) ; Alfacalcidol (DB01436) ; Fluspirilene (DB04842) ; Azilsartan medoxomil (DB08822) ; Cabozantinib (DB08875) ; Lorpiprazole (DB09195) Ergocalciferol (DB00153) ; Loperamide (DB00836) ; Drospirenone (DB01395) Pranlukast (DB01411) ; Ziprasidone (DB00246) ; Meclizine (DB00737) ; Sertindole (DB06144) ; Lurasidone (DB08815) ; Vorapaxar (DB09030) ; Umeclidinium (DB09076) ; ABR- 238901; Tasquinimod (ABR-215050) ; Paquinimod (ABR 25757) ; laquinimod (ABR-215062 ) ; Roquinimex (ABR212626) , Azeliragon; FPS-ZM1; RAGE 229; AC-73; antagonist peptide-9 (AP9) and combinations thereof. Lisbon, 6<th>December 2024